Tetraphase Pharmaceuticals' TP-6076 selected by CARB-X to receive $4 million
Tetraphase announced that its pipeline candidate TP-6076 was selected to receive $4 million in research funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), an international, public-private partnership focused on development of new antimicrobial products. March 30, 2017